Breast cancer is the most common malignant tumor among women. In recent years，research data show that early diagnosis and treatment can significantly reduce the mortality of patients with cancer. Positron mission computed tomography（PET/CT）is a noninvasive and systemic imaging method which integrates function and anatomy，and plays an important role in the clinical staging and guiding treatment of brenst cancer. 18F-fluorodeoxyglucose（18F-FDG） is the most widely used imaging agent. Because of non-specificity，its application in breast cancer patients is limited to some extent. Therefore，for the past few years，there were more researches on the specific receptor imaging agents for breast cancer patients. This paper reviews the development and clinical application of new molecular targeted positron drugs in PET imaging of breast cancer.